- Dubai Struggles to Ease Debt Fears; Investors Rattled
- Fannie Mae to Tighten Lending Standards: Report
- Black Friday to Avoid Red Ink; Greenback Gets the Blues
- Investing in Good Karma – and Making a Profit
- Retailers Should Believe in Christmas Miracles
- Wal-Mart Price Pressure Hurts China Workers: Report
- Bankruptcies Jump, Hitting Highest Level in Four Years
- Steepest Black Friday Discounts, Revealed
- Where Do Pardoned Turkeys Go?
- 4 Thanksgiving Week Buys For Your Portfolio: Market Pros
- There's a 'Great Chance' For a Double-Dip Recession: Strategist
- Revenge of the Gangsta Nerds
- Will TCU See The "Flutie Effect?"
- Retail Earnings and Sales to Improve in Q4: Analyst
- Consumers Catching the Holiday Spirit
- It's Beginning To Look A Lot More Riskless
- Crescenzi: Claims Level Suggests End to Job Losses
- Hedge Funds Take Early Lead in Warren Buffett's 'Big Bet'
- Perry leads Texas GOP fight against climate bill
- Robotic hamsters are holidays' unlikely new craze
- Bookstore chain Borders UK appoints administrators
- Immigration reform activists diversifying ranks
- Tommy Hilfiger's estate in Conn. sells for $20M
- Repsol says it will invest $1.5 billion in Bolivia
- Belgium reluctant to renew GM loan offer
- Business software firm RedPrairie files for IPO
- Reports: Police probe Vatican bank transactions
NEW YORK - Newer anti-psychotic drugs are no safer than older ones for the risk of suddenly dying from a heart problem, says a study that finds they roughly double that hazard.
The older drugs had already been linked to an increased chance of sudden cardiac death, in which the heart loses its normal rhythm and can't pump blood normally.
The older and newer anti-psychotics had also been shown to boost the risk of death when used to treat agitation, aggression and delusions in elderly dementia patients. The new study was conducted among a much broader group of adults, with an average age of 46 and various psychiatric problems.
Anti-psychotic drugs are approved for treating schizophrenia and bipolar disorder, which is also called manic-depression, but doctors can legally prescribe them for any other use.
The new, federally funded study appears in Thursday's issue of the New England Journal of Medicine.
Replacing older meds
Researchers examined Tennessee Medicaid records covering the 15 years ending in 2005. They focused on about 44,000 users of older anti-psychotic drugs like haloperidol and about 46,000 users of newer drugs like Zyprexa, made by Indianapolis-based Eli Lilly & Co., and Risperdal, made by New Brunswick, N.J.-based Johnson & Johnson Inc.
The newer drugs have largely replaced the older medications in patient care.
INTERACTIVE |
Some 1,900 participants died of sudden cardiac death over the 15 years. Analysis found that taking either the older or the newer drugs roughly doubled the risk of sudden cardiac death. The overall rate in drug users was about three deaths per year for every 1,000 patients.
"To me, three per thousand is frequent enough (that) I would take it into account for a family member or friend," said Wayne Ray of Vanderbilt University in Nashville, Tenn., a study author.
Ray stressed that patients should not simply stop taking the drugs, but should speak to their doctors. He noted that people with schizophrenia or a related psychosis have no real alternative to anti-psychotic drugs. Perhaps they should get heart examinations before going on the drugs, and take steps to reduce their risk of sudden cardiac death, he said.
There are alternatives for treating bipolar disorder, he said. And for other uses, anti-psychotics should be considered "a very last resort, to be used sparingly," he recommended.
In a journal editorial, Drs. Sebastian Schneeweiss and Jerry Avorn of Harvard Medical School said the study "makes a clear case" for increased risk of the heart problem from all anti-psychotics.
- For nearly three decades, these on-call experts have been dishing advice on how to – and not to – cook turkey.
- Ever wished your cab driver would stop nattering and just get to where you're going? Well that moment is near(er).
- Eric Schmidt pledges to create a virtual copy of the Iraq National Museum at Google’s expense.
- Bill Griffeth is taking a leave of absence from CNBC and Power Lunch for a year. Here's a message from Bill.
- More shoppers than ever plan to comparison-shop this season. Who will benefit?
- It may be the most unusual guide to business you'll read.









